Comparison of Safety and Efficacy of Intravitreal Ziv-Aflibercept Vs Bevacizumab for the Treatment of Macular Edema

• DOI: 10.36351/pjo.v36i3.1014
• Publication Date: 2020-07-08T12:40:10Z
• Authors: Hussain Ahmad Khaqan; Usman Imtiaz; Hasnain Muhammad ...; Hafiz Ateeq Ur Re...; Raheela Naz
• Keywords: Aflibercept

Purpose: To study the safety and efficacy of intravitreal Ziv-Aflibercept vs. Bevacizumab for management edema caused by different retinal pathologies.
 Study Design: Comparative interventional study.
 Place Duration Study: Lahore General Hospital, Lahore, from July 2018 to June 2019.
 Material Methods: Patients with resistant, center involving macular due diabetes, vein occlusion age related degeneration were recruited. Complete ocular examination was performed. All patients randomly grouped into two i.e. IVZ (intravitreal Ziv-Aflibercept) IVB bevacizumab). Each eye underwent injection 0.05 ml fresh filtered ziv-aflibercept (1.25 mg) or Bevacizumab. Outcome measured in terms variation central thickness (CMT) also best corrected visual acuity (BCVA) at 3 months.
 Results: Total 156 eyes 136 completed whole duration included results. The mean baseline CMT 510 μm (± 94 μm) group 493μm (±102 (P = 0.94). BCVA (log MAR) 0.78 (Snellen's equivalent 6/36) 0.70 6/30) 0.78). Central significantly reduced 1st, 2nd 3rd month < 0.001).
 Conclusion: Intravitreal is safe more effective than treatment diabetes mellitus, wet degeneration.